{"filing":{"accession_number":"0001648257-26-000039","cik":"0001648257","ticker":"HMDCF","company_name":"HUTCHMED (China) Ltd","form":"6-K","filing_date":"2026-06-12","report_date":null,"primary_document":"hcm-20260612x6k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1648257/000164825726000039/hcm-20260612x6k.htm"},"events":[{"id":12185,"run_id":10748,"accession_number":"0001648257-26-000039","anchor_item_number":"EX-99.1","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.75,"summary":"This press release announces Phase III clinical trial results for sovleplenib (ESLIM-02 study) in warm antibody autoimmune hemolytic anemia, presented at EHA 2026 Congress. The disclosure highlights that the study met its primary endpoint with statistically significant efficacy data (66% durable response vs 15% placebo, p\u003c0.0001) and a favorable safety profile. While this is a clinical milestone rather than financial results, it represents a material operational and regulatory event: the NMPA has accepted the NDA for priority review and granted Breakthrough Therapy Designation, positioning sovleplenib as a potential commercial product addressing an unmet medical need in a treatment-sparse landscape. The data directly supports regulatory advancement and future revenue potential.","company_name":"HUTCHMED (China) Ltd","ticker":"HMDCF","filing_date":"2026-06-12","form":"6-K","submitted_at":null,"items":[{"id":8972,"accession_number":"0001648257-26-000039","item_number":"EX-99.1","item_title":"hcm-20260612xex99d1.htm","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.75,"reasoning":"This press release announces Phase III clinical trial results for sovleplenib (ESLIM-02 study) in warm antibody autoimmune hemolytic anemia, presented at EHA 2026 Congress. The disclosure highlights that the study met its primary endpoint with statistically significant efficacy data (66% durable response vs 15% placebo, p\u003c0.0001) and a favorable safety profile. While this is a clinical milestone rather than financial results, it represents a material operational and regulatory event: the NMPA has accepted the NDA for priority review and granted Breakthrough Therapy Designation, positioning sovleplenib as a potential commercial product addressing an unmet medical need in a treatment-sparse landscape. The data directly supports regulatory advancement and future revenue potential.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-06-22T02:22:13.642611+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":8972,"accession_number":"0001648257-26-000039","item_number":"EX-99.1","item_title":"hcm-20260612xex99d1.htm","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.75,"reasoning":"This press release announces Phase III clinical trial results for sovleplenib (ESLIM-02 study) in warm antibody autoimmune hemolytic anemia, presented at EHA 2026 Congress. The disclosure highlights that the study met its primary endpoint with statistically significant efficacy data (66% durable response vs 15% placebo, p\u003c0.0001) and a favorable safety profile. While this is a clinical milestone rather than financial results, it represents a material operational and regulatory event: the NMPA has accepted the NDA for priority review and granted Breakthrough Therapy Designation, positioning sovleplenib as a potential commercial product addressing an unmet medical need in a treatment-sparse landscape. The data directly supports regulatory advancement and future revenue potential.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-06-22T02:22:13.642611+00:00","company_name":"HUTCHMED (China) Ltd","ticker":"HMDCF","filing_date":"2026-06-12"}]}